Efficacy of FOLFIRI plus bevacizumab versus FOLFIRI plus cetuximab in RAS-mutant metastatic colorectal cancer: Final update on patients with RAS-mutant metastatic colorectal cancer treated in FIRE-3

被引：0
|
作者：
Weiss, Lena
Stintzing, Sebastian
Modest, Dominik Paul
von Weikersthal, Ludwig
Decker, Thomas
Kiani, Alexander
Vehling-Kaiser, Ursula
Al-Batran, Salah-Eddin
Heintges, Tobias
Lerchenmuller, Christian A.
Kahl, Christoph
Seipelt, Gernot
Kullmann, Frank
Moehler, Markus H.
Scheithauer, Werner
Held, Swantje
Miller-Phillips, Lisa
Stahler, Arndt
Jung, Andreas
Heinemann, Volker
机构：
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[2] Charit Univ Med Berlin, Hematol Oncol & Canc Immunol CCM, Berlin, Germany
[3] Charite Univ Med Berlin, Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[4] Gesundheitszentrum St Marien GmbH, Amberg, Germany
[5] Onkol Ravensburg, Ravensburg, Germany
[6] Klinikum Bayreuth GmbH, Dept Hematol & Oncol, Bayreuth, Germany
[7] Comprehens Canc Ctr EMN, Erlangen, Germany
[8] Practice Med Oncol, Landshut, Germany
[9] Univ Canc Ctr Germany, Frankfurt Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[10] Stadtische Kliniken Neuss, Neuss, Germany
[11] Hamatolog Onkolog, Greven, Germany
[12] Klinikum Magdeburg, Dept Hematol, Magdeburg, Germany
[13] Onkolog Schwerpunktpraxis, Dreieich, Germany
[14] Klinikum Weiden, Dept Med 1, Weiden, Germany
[15] Johannes Gutenberg Univ Clin, Mainz, Germany
[16] Med Univ Vienna, Vienna, Austria
[17] Clinassess Inc, Leverkusen, Germany
[18] Univ Munich, LMU Klinikum, Munich, Germany
[19] Charit Univ Med Berlin, Berlin, Germany
[20] Free Univ Berlin, Berlin, Germany
[21] Humboldt Univ, Berlin, Germany
[22] Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[23] Univ Munich, Inst Pathol, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3550
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer
    He, Wen-zhuo
    Jiang, Chang
    Yi, Jiahong
    Xue, Ju
    Yin, Zhao-feng
    Dong, Wen-jing
    Xia, Liang-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer
    Huang, Weizhen
    Zhang, Hang
    Tian, Yunming
    Cha, Yinlian
    Xiong, Hailin
    Yuan, Xia
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (04) : 531 - 538
  • [3] BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)
    Stintzing, S.
    von Weikersthal, L. Fischer
    Decker, T.
    Kiani, A.
    Vehling-Kaiser, U.
    Al-Batran, S. -E.
    Heintges, T.
    Lerchenmueller, C.
    Kahl, C.
    Seipelt, G.
    Kullmann, F.
    Stauch, M.
    Hielscher, J.
    Lerch, M.
    Scheithauer, W.
    Jagenburg, A.
    Held, S.
    Modest, D.
    Jung, A.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2016, 27 : 112 - 112
  • [4] Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
    Laura E. Fischer
    Sebastian Stintzing
    Ludwig Fischer von Weikersthal
    Dominik P. Modest
    Thomas Decker
    Alexander Kiani
    Florian Kaiser
    Salah-Eddin Al-Batran
    Tobias Heintges
    Christian Lerchenmüller
    Christoph Kahl
    Gernot Seipelt
    Frank Kullmann
    Martina Stauch
    Werner Scheithauer
    Clemens Giessen-Jung
    Jens Uhlig
    Bettina Peuser
    Claudio Denzlinger
    Arndt Stahler
    Lena Weiss
    Kathrin Heinrich
    Swantje Held
    Andreas Jung
    Thomas Kirchner
    Volker Heinemann
    British Journal of Cancer, 2022, 127 : 836 - 843
  • [5] Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
    Fischer, Laura E.
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Modest, Dominik P.
    Decker, Thomas
    Kiani, Alexander
    Kaiser, Florian
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Giessen-Jung, Clemens
    Uhlig, Jens
    Peuser, Bettina
    Denzlinger, Claudio
    Stahler, Arndt
    Weiss, Lena
    Heinrich, Kathrin
    Held, Swantje
    Jung, Andreas
    Kirchner, Thomas
    Heinemann, Volker
    BRITISH JOURNAL OF CANCER, 2022, 127 (05) : 836 - 843
  • [6] Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
    Yanrong Wang
    Ru Jia
    Haiyan Si
    Yue Ma
    Mengjiao Fan
    Nan Zhang
    Fangfang Liu
    Yue Shi
    Yushan Jia
    Yaoyue Zhang
    Quanli Han
    Zhikuan Wang
    Guanghai Dai
    BMC Cancer, 25 (1)
  • [7] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    Heinemann, Volker
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Hielscher, Joerg
    Scholz, Michael
    Mueller, Sebastian
    Link, Hartmut
    Niederle, Norbert
    Rost, Andreas
    Hoeffkes, Heinz-Gert
    Moehler, Markus
    Lindig, Reinhard U.
    Modest, Dominik P.
    Rossius, Lisa
    Kirchner, Thomas
    Jung, Andreas
    Stintzing, Sebastian
    LANCET ONCOLOGY, 2014, 15 (10): : 1065 - 1075
  • [8] Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
    Bouchahda, Mohamed
    Saffroy, Raphael
    Karaboue, Abdoulaye
    Hamelin, Jocelyne
    Innominato, Pasquale
    Saliba, Faouzi
    Levi, Francis
    Bosselut, Nelly
    Lemoine, Antoinette
    JCO PRECISION ONCOLOGY, 2020, 4 : 1070 - 1079
  • [9] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
    Stintzing, Sebastian
    Modest, Dominik P.
    Rossius, Lisa
    Lerch, Markus M.
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Kiani, Alexander
    Vehling-Kaiser, Ursula
    Al-Batran, Salah-Eddin
    Heintges, Tobias
    Lerchenmueller, Christian
    Kahl, Christoph
    Seipelt, Gernot
    Kullmann, Frank
    Stauch, Martina
    Scheithauer, Werner
    Held, Swantje
    Giessen-Jung, Clemens
    Moehler, Markus
    Jagenburg, Andreas
    Kirchner, Thomas
    Jung, Andreas
    Heinemann, Volker
    LANCET ONCOLOGY, 2016, 17 (10): : 1426 - 1434
  • [10] Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab
    Al-Shamsi, Humaid O.
    Anjum, Mahraz
    Al Farsi, Abdulaziz
    Shen, Hua
    Linkins, Lori-Ann
    Cook, Richard J.
    Major, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345